KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis.

Tristan Curteis, Lucy A Eddowes, Andrei Karlsson, Hannah Luedke, Manon Rubinstein, Mathias Hempfling, Jonathan Gurney, Bhumi Gandhi-Patel, Nathan Unger, Uche Mordi, Megan Chen, James Jarrett, Elizabeth M Sherman, Karam Mounzer, Ann M Khalsa, Warren L Dinges, Mehri S McKellar, Ashley Lipps

J Comp Eff Res 15(6) e260013

PMID42206806
PMCIDPMC13248988
DOI10.57264/cer-2026-0013
发表日期2026-05-28
摘要

摘要

Aim: With modern antiretroviral therapy (ART), HIV-1 has now become a manageable chronic condition. Among treatment-experienced (TE) people with HIV-1 (PWH), ART regimens can influence metabolic and renal outcomes and adverse events such as nausea. Regimen selection increasingly prioritizes safety, tolerability and long-term acceptability. This study compared bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with other ART regimens in TE PWH using multilevel network meta-regression (ML-NMR), focusing on lipid profile, renal function and overall safety. Materials & methods: A systematic literature review (SLR) in June 2023 identified Phase III/IV randomized controlled trials reporting safety in adult TE PWH. ML-NMR was conducted at week 48 adjusting for age, sex, race and CD4 cell count, using individual patient data from three Phase III B/F/TAF trials (GS-US-380-1844, -1878, -4030) and aggregate data from comparator trials. Results: At week 48, B/F/TAF demonstrated similar changes in total cholesterol (TC) to HDL ratio and LDL versus comparators. Compared with NNRTI (+ or /) F/TDF, changes in TC favored B/F/TAF (mean difference [MD; 95% CrI]: -12.43 [-23.26, -1.53]), but favored the NNRTI-based regimen for HDL (-4.35 [-7.76, -0.70]). Triglycerides changes favored B/F/TAF versus DTG/ABC/3TC (-15.01 [-29.18, -1.06]) and protease inhibitor (+ or /) b + 2 NRTIs (-24.48 [-41.60, -7.47]). eGFR changes favored B/F/TAF versus DTG/ABC/3TC (3.81 [1.74, 5.97]). With some exceptions of statistical differences in both directions, B/F/TAF generally had similar levels of adverse events and discontinuations as other ART. Conclusion: Switching to or remaining on B/F/TAF in TE PWH was generally well tolerated and did not worsen lipid, renal or safety outcomes versus most other contemporary ART. Improvements in select lipid parameters and stable renal function, with low rates of adverse events and discontinuation, support B/F/TAF as a safe option for long-term management in TE PWH.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。